SPAIN; UNITED STATES OF AMERICA —Medical technology developer Anaconda Biomed has successfully closed a USD 56 million financing round to accelerate the clinical and commercial progression of its neurovascular intervention portfolio. The capital injection was spearheaded by Omega Funds, with fresh participation from the Spanish Co-investment Fund, managed by COFIDES. Existing backers, including Asabys Sabadell, Ysios Capital, and the Spanish Center for Industrial Technological Development via its SICC Innvierte program, also reinforced their commitments.
The newly secured capital is strategically allocated to finalize the ATHENA pivotal Investigational Device Exemption study. This prospective, randomized trial involves 327 subjects and is designed to rigorously evaluate the safety and efficacy of the ANA Funnel Catheter. Furthermore, the funds will underpin continuous product innovation and facilitate comprehensive regulatory submissions across international markets.
This development is highly significant for the medical device sector, particularly within the neurovascular and stroke treatment segments. As global healthcare systems seek to minimize stroke-related mortality and long-term disability, advanced endovascular tools that improve clot retrieval and reduce embolic complications are in critical demand. The successful fundraising underscores a robust market appetite for innovative mechanical thrombectomy solutions that can enhance patient outcomes during acute ischemic events.
For investors and industry stakeholders, this financing validates the commercial viability of the proprietary platform. Anaconda Biomed is a medical technology firm specializing in next-generation thrombectomy catheters. Its proprietary platform merges the high aspiration capacity of large-bore systems with the flow-arrest advantages of balloon guide catheters to optimize brain reperfusion. This dual-mechanism approach aims to capture microemboli proactively, thereby minimizing the number of device passes required during complex procedures.
Geographically, the involvement of prominent Spanish investment vehicles highlights the growing strength of the European health technology ecosystem in nurturing deep-tech medical innovations. Concurrently, the focus on United States regulatory pathways indicates a strategic prioritization of the world’s largest medical device market, where the primary catheter currently maintains investigational status, while specific variants have already secured European CE marking.
